3상모집 중

A Study of Daratumumab

연구 개요

The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.

스폰서
리드: 얀센(J&J)
적응증
Multiple Myeloma
중재
Daratumumab, Carfilzomib, Dexamethasone, Lenalidomide, Pomalidomide
목표 등록
500
시작일
2022-12-15
완료(예정)
2029-12-31

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.